|
Zai Lab Limited (NASDAQ: ZLAB) |
|
Zai Lab Limited
ZLAB's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Zai Lab Limited growth rates, revenue grew
by 22.19 % in the first quarter of 2025 from the same quarter a year ago.
Ranking at No. 540
Major Pharmaceutical Preparations industry recorded
growth of revenues by 3.97 %
Zai Lab Limited net loss decreased from $-53 millions, to $-48 millions in first quarter of 2025,
• More on ZLAB's Growth
|
|
Zai Lab Limited realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 284.51 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 72.42.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.02.
• More on ZLAB's Valuation
|
|
|
|
|
Zai Lab Limited realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 284.51 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 72.42.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.02.
Zai Lab Limited Price to Book Ratio is at 37.37 lower than Industry Avg. of 75.38. and higher than S&P 500 Avg. of 0.01
• More on ZLAB's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com